Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novira: Capsid counterattack

Novira developing therapeutics against viral capsids for HBV, HIV

Developing compounds against viral capsids is an attractive therapeutic strategy in theory, but has yet to work in practice because of the difficulty of inhibiting protein-protein interactions. Novira Therapeutics Inc. believes it has the right medicinal chemistry capabilities to develop small molecules that prevent capsid formation in HBV and HIV.

The capsid is a protein shell that forms around a virus to protect it during passage from one cell to another. "They do not have obvious binding sites, so there was

Read the full 805 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers